2 results
Approved WMOCompleted
The aim of this prospective, multicentre randomized phase II study is to evaluate the safety and efficacy of the combination of capmatinib and spartalizumab in subjects with EGFR weight (for exon 19 deletions and exon 21 L858R substitution mutations…
Approved WMOCompleted
To evaluate the efficacy of each combination arm, as measured by confirmed objective response rate (ORR)